Poster Presentation to Focus on Reqorsa's
Ability to Modulate In Vivo Immune Responses Against
Cancers
AUSTIN,
Texas, Oct. 7, 2024 /PRNewswire/ -- Genprex, Inc.
("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage
gene therapy company focused on developing life-changing therapies
for patients with cancer and diabetes, today announced that its
research collaborators at Meharry Medical
College were selected to present at the upcoming
39th Annual Society for Immunotherapy of Cancer Meeting
being held November 6-10, 2024 in
Houston, Texas. The collaborators
will present a poster on positive preclinical data from a study of
the Company's lead drug candidate, Reqorsa® Gene Therapy
(quaratusugene ozeplasmid) evaluating TUSC2's role in
modulating immune responses in cancer.
"The body of preclinical evidence supporting
REQORSA's potential in the treatment of a variety of cancers
continues to grow as we bolster our robust research program for
REQORSA with our collaborators at many academic institutions," said
Ryan Confer, President and Chief
Executive Officer at Genprex. "We are very pleased that our
academic partners have been selected to present their findings on
REQORSA at this prestigious cancer meeting, and we look forward to
this presentation next month sharing more about TUSC2's role in
modulating immune responses in cancer."
The featured Genprex-supported poster to be
presented at the 2024 Society for Immunotherapy of Cancer Annual
Meeting:
Title: "TUSC2 Modulates Cancer Immune
Responses"
Collaborator: Meharry Medical
College
TUSC2 is the tumor suppressor gene used in
REQORSA. REQORSA consists of a TUSC2 gene expressing plasmid
encapsulated in non-viral lipid-based nanoparticles in
a lipoplex form (the Company's Oncoprex®
Delivery System), which has a positive charge. REQORSA is injected
intravenously and specifically targets cancer cells. REQORSA is
designed to deliver the functioning TUSC2 gene to negatively
charged cancer cells while minimizing uptake by normal tissue.
Laboratory studies conducted at MD Anderson show that the
uptake of TUSC2 in tumor cells in vitro after REQORSA treatment
was 10 to 33 times the uptake in normal cells.
About Genprex, Inc.
Genprex, Inc. is a
clinical-stage gene therapy company focused on developing
life-changing therapies for patients with cancer and diabetes.
Genprex's technologies are designed to administer disease-fighting
genes to provide new therapies for large patient populations with
cancer and diabetes who currently have limited treatment options.
Genprex works with world-class institutions and collaborators to
develop drug candidates to further its pipeline of gene therapies
in order to provide novel treatment approaches. Genprex's oncology
program utilizes its systemic, non-viral Oncoprex®
Delivery System which encapsulates the gene-expressing plasmids
using lipid-based nanoparticles in a lipoplex form. The resultant
product is administered intravenously, where it is taken up by
tumor cells that then express tumor suppressor proteins that were
deficient in the tumor. The Company's lead product candidate,
Reqorsa® Gene Therapy (quaratusugene ozeplasmid), is
being evaluated in two clinical trials as a treatment for NSCLC and
SCLC. Each of Genprex's lung cancer clinical programs has received
a Fast Track Designation from the FDA for the treatment of that
patient population, and Genprex's SCLC program has received an FDA
Orphan Drug Designation. Genprex's diabetes gene therapy approach
is comprised of a novel infusion process that uses an AAV vector to
deliver Pdx1 and MafA genes directly to the pancreas. In models of
Type 1 diabetes, GPX-002 transforms alpha cells in the pancreas
into functional beta-like cells, which can produce insulin but may
be distinct enough from beta cells to evade the body's immune
system. In a similar approach, GPX-002 for Type 2 diabetes, where
autoimmunity is not at play, is believed to rejuvenate and
replenish exhausted beta cells.
Interested investors and shareholders are
encouraged to sign up for press releases and industry updates by
visiting the Company Website, registering for Email
Alerts and by following Genprex on Twitter, Facebook and
LinkedIn.
Cautionary Language Concerning Forward-Looking
Statements
Statements contained in this press release
regarding matters that are not historical facts are
"forward-looking statements" within the meaning of the Private
Securities Litigation Reform Act of 1995. These forward-looking
statements are made on the basis of the current beliefs,
expectations and assumptions of management, are not guarantees of
performance and are subject to significant risks and uncertainty.
These forward-looking statements should, therefore, be considered
in light of various important factors, including those set forth in
Genprex's reports that it files from time to time with the
Securities and Exchange Commission and which you should review,
including those statements under "Item 1A – Risk Factors" in
Genprex's Annual Report on Form 10-K for the year ended
December 31, 2023.
Because forward-looking statements are subject to
risks and uncertainties, actual results may differ materially from
those expressed or implied by such forward-looking statements. Such
statements include, but are not limited to, statements regarding:
Genprex's ability to advance the clinical development,
manufacturing and commercialization of its product candidates in
accordance with projected timelines and specifications; the timing
and success of Genprex's clinical trials and regulatory approvals;
the effect of Genprex's product candidates, alone and in
combination with other therapies, on cancer and diabetes; the
effects of any strategic research and development prioritization
initiatives, and any other strategic alternatives or other efforts
that Genprex takes or may take in the future that are aimed at
optimizing and re-focusing Genprex's diabetes, oncology and/or
other clinical development programs including prioritization of
resources, and the extent to which Genprex is able to implement
such efforts and initiatives successfully to achieve the desired
and intended results thereof; Genprex's future growth and financial
status, including Genprex's ability to maintain compliance
with the continued listing requirements of The Nasdaq Capital
Market and to continue as a going concern and to obtain capital to
meet its long-term liquidity needs on acceptable terms, or at all;
Genprex's commercial and strategic partnerships, including those
with its third party vendors, suppliers and manufacturers and their
ability to successfully perform and scale up the manufacture of its
product candidates; and Genprex's intellectual property and
licenses.
These forward-looking statements should not be
relied upon as predictions of future events and Genprex cannot
assure you that the events or circumstances discussed or reflected
in these statements will be achieved or will occur. If such
forward-looking statements prove to be inaccurate, the inaccuracy
may be material. You should not regard these statements as a
representation or warranty by Genprex or any other person that
Genprex will achieve its objectives and plans in any specified
timeframe, or at all. You are cautioned not to place undue reliance
on these forward-looking statements, which speak only as of the
date of this press release. Genprex disclaims any obligation to
publicly update or release any revisions to these forward-looking
statements, whether as a result of new information, future events
or otherwise, after the date of this press release or to reflect
the occurrence of unanticipated events, except as required by
law.
Genprex, Inc.
(877) 774-GNPX (4679)
GNPX Investor
Relations
investors@genprex.com
GNPX Media Contact
Kalyn Dabbs
media@genprex.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/genprex-collaborators-to-present-positive-preclinical-data-on-reqorsa-gene-therapy-at-the-society-for-immunotherapy-of-cancer-2024-annual-meeting-302268681.html
SOURCE Genprex, Inc.